Debate

Acute treatment of migraine. Breaking the paradigm of monotherapy
Abouch Valenty Krymchantowski*

Address: Department of Neurology, Universidade Federal Fluminense, Rio de Janeiro, Brazil. Headache Outpatient Service, Instituto de Neurologia Deolindo Couto, Rio de Janeiro, Brazil. Headache Center of Rio, Rio de Janeiro, Brazil

Email: Abouch Valenty Krymchantowski* - abouchkrym@globo.com
* Corresponding author

Abstract

Background: Migraine is a highly prevalent disorder. The disability provoked by its attacks results in suffering as well as considerable economic and social losses. The objective of migraine acute treatment is to restore the patient to normal function as quickly and consistently as possible. There are numerous drugs available for this purpose and despite recent advances in the understanding of the mechanisms and different biological systems involved in migraine attacks, with the development of specific 5-HT agonists known as triptans, current options for acute migraine still stand below the ideal.

Discussion: Monotherapeutic approaches are the rule but up to one third of all patients discontinue their medications due to lack of efficacy, headache recurrence, cost and/or side effects. In addition, a rationale has been suggested for the development of polytherapeutic approaches, simultaneously aiming at some of the biological systems involved. This paper reviews the fundamentals for this changing approach as well as the evidence of its better efficacy.

Conclusion: As a conclusion, most of the patients with a past history of not responding (no pain-free at 2 hours and/or no sustained pain-free at 24 hours) in at least 5 previous attacks should undergo a combination therapy suiting to their individual profile, which must include analgesics or non-steroidal anti-inflammatory agents plus a triptan or a gastro kinetic drug. The three-drug regimen may also be considered. In addition, changing the right moment to take it and the choice for formulations other than oral has also to be determined individually and clearly posted to the patient.

Background

Migraine is a highly prevalent disorder which manifests clinically as moderate to severe or severe headache attacks with frequent frontotemporal unilateral location and associated symptoms [1-3]. The pain is pulsating and/or pressure-type, usually associated with nausea, photophobia, phonophobia and osmophobia. Its attacks promote disability and generally worsen with physical activities. The duration may last from 4 to 72 hours when not treated or treated ineffectively [3]. The headache frequency is variable and some patients may present it on a weekly basis while others will have it less than once a
month [4]. The disability of migraine results in considerable economic and social losses [5].

Migraine attacks may present with four distinct phases: (1) prodromic phase with premonitory symptoms, (2) aura phase with transient neurological symptoms and signs, (3) headache phase with associated features and (4) recovery or postdromic phase frequently associated with resting and sleeping. Only the headache phase can be treated and despite the advances in understanding migraine, considerable uncertainty surrounding an effective and definitive way of treating the attacks remains [6,7].

The objective of acute migraine therapy is to restore the patient to normal function by rapidly and consistently alleviating the headache and the associated symptoms of nausea, vomiting and sensory phobias without side effects and recurrence of the attack within 24 hours [8]. Several drug options and different formulations are available to treat migraine acutely. The choice of a specific medication type depends on individual characteristics such as headache intensity, speed of onset of action, presence of associated symptoms, the degree of incapacitation, and the patient’s response [9].

There are specific and non-specific treatments for migraine attacks. Non-specific treatments, such as aspirin, acetaminophen, non-steroidal anti-inflammatory drugs (NSAIDs), opioids, and combination analgesics, are used to treat migraine and a wide range of pain disorders [10]. Specific treatments, including ergotamine, dihydroergotamine and the triptans are effective for treating the attacks of primary headaches with neurovascular mechanisms, such as migraine and cluster headache, but not for treating other types of headaches [11].

**Discussion**

**Reasons for changing the approach**

Clinicians know that some patients do respond well to simple analgesics in a monotherapeutic approach but despite the advent of newer, highly effective migraine acute therapies, most of the patients still want rapid onset of complete pain relief [12], which cannot be provided by most of the current individual options for migraine treatment [13]. Although the triptans represented a tremendous positive impact on patient care and clinical practice, they are still far away from the optimum. Monotherapy using these selective 5-HT1B/1D agonists, especially orally, does not result in rapid, consistent, and complete relief of migraine in all patients [14]. The response rates in numerous controlled trials vary considerably. The aura phase of patients with migraine with aura can’t be effectively treated, side effects may occur in up to 89% of the patients and up to 31% of those taking sumatriptan continue its use due to lack of efficacy, headache recurrence, cost and/or side effects [15-18]. In addition, most of these studies were performed using the endpoint headache relief (from moderate or severe to mild or none) rather than the current standard of headache free at 2 hours [19]. Moreover, due to variable placebo response rates, one must have to pursue parameters of therapeutic gain instead of absolute response [20].

Subcutaneous sumatriptan for instance, still considered the most efficacious drug for a migraine attack, promotes headache relief with a therapeutic gain of 51–52% [20]. The other triptans and triptan formulations range from 10 to 47% with regard to therapeutic gain. On the other hand, ergotamine derivatives have been used for over 40 years but little evidence exists that it is significantly more effective than placebo [21]. Although largely used in some countries, its pharmacokinetic is totally unpredictable, with oral and rectal bioavailability of less than 5%, which do not provide consistency through all attacks within the same patient [22,23]. Other options for migraine attacks include analgesics alone or combined with caffeine and/or metoclopramide and NSAID. These compounds vary largely in characteristics but in regard to efficacy may demonstrate therapeutic gains similar to 100 mg sumatriptan (around 29–30%) [24]. Recurrence, the returning of the headache within 24 hours after it has become mild or absent, is also a problem with triptans and with other acute migraine treatments. The use of sumatriptan, for example, may bring up recurrence after 6–7 h with the nasal spray, after 17 h with the tablets and after 10 h with the subcutaneous formulation [25]. The recurrence may require re-dosing, which can cause excessive use and more dissatisfaction with available treatments [26].

In addition, recent evidence has demonstrated that once peripheral and central sensitization occurs and allodynia cutanea develops, the triptans and other acute therapies will not work efficiently in order to provide consistent relief [27]. Moreover, migraine seems to involve different pathophysiological mechanisms named as “low” serotonin, neurogenic inflammation and dopaminergic hypersensitivity which implies that addressing one of the involved biological systems will always stand below the ideal [14]. The consistent demonstration of changes in 5-HT levels during migraine has ever been found in all migraineurs but alterations in 5-HT levels in metabolism have been reported by many investigators [14,28]. The inflammation in migraine is crucial. Transient disturbances in cortical sensory functions release potassium and hydrogen ions in the vicinity of sensory fibers that inner- vate the dura, which could activate C-fiber meningeal nociceptors and secretion of calcitonin-gene-related-peptide, therefore initiating neurogenic inflammation.
[29,30] with the introduction of histamine, serotonin, bradykinin, and prostaglandins into this environment.

Mechanical hypersensitivity develops in receptors located in the dura mediating the throbbing of the headache and it’s worsening during coughing, bending, or other physical activities that increase intracranial pressure [31]. In addition, the inflammation activates and sensitizes dorsal horn neurons leading to cutaneous allodynia in the ipsilateral periorbital skin followed by the expanding of receptive fields to the contralateral periorbital areas as well [32]. Finally, dopaminergic hypersensitivity has been documented in migraine by data demonstrating that migraineurs are more sensitive to the effects of dopaminergic agonists than nonmigraineurs. It is corroborated by the observation that many components of a migraine attack such as yawning, nausea, hypotension, cerebral blood flow changes and headache are induced by doses of dopamine agonists that have no effect in nonmigraineurs [14,33-36]. All of these facts point to a path of combining drugs aiming at different mechanisms and systems involved in migraine, at least in certain subsets of patients not responsive to traditional approaches, with regard to pain-free and sustained pain-free endpoints. But, does the simultaneous action on various pathophysiological mechanisms really improve efficacy and outcome?

**Evidence of better efficacy**

Monotherapeutic approaches to each of the biological systems involved in migraine result in definite, but often suboptimal, relief of a migraine attack. Therefore, it follows logically that polytherapy targeting more than one of these systems should be more efficacious than addressing only a single mechanism involved in migraine pathophysiology [14]. In addition, drugs rapid achieving onset of action could be able to function before the central sensitization and development of cutaneous allodynia, providing better consistency across multiple attacks. Even prior to the introduction of 5-HT agonists, it was demonstrated that combining therapies result in better outcome. Lance recommended metoclopramide to be given before the administration of an ergot derivative in order to allow a faster gastric absorption, which is impaired during a migraine attack [37]. Wilkinson reported that 61% of her patients had total or significant relief of migraine following a regimen that included a dopamine antagonist, a simple analgesic, and an attempt to sleep. In the remaining patients, an ergot preparation was added and resulted in a total efficacy rate of 91% [38]. The combination of dihydroergotamine (DHE) plus prochlorperazine administered intravenously revealed to be a highly effective emergency room scheme as proposed by Callaham and Raskin [39]. We have been demonstrating that the combination of sumatriptan plus a NSAID such as tolfenamic acid or naproxen sodium reduces recurrence in clinical practice. In our first study, 240 moderate or severe attacks were treated with 100 mg sumatriptan and 200 mg of tolfenamic acid resulting in a decreasing recurrence rate from 62.5% to 23.8%. However, this was an open retrospective study, therefore, limiting further conclusions [40].

On the other hand, the use of 100 mg sumatriptan and 550 mg naproxen sodium reduced recurrence from 59% to 25.5% (p < 0.0003) compared to the use of sumatriptan plus placebo [41]. Another 5-HT agonist, the Rizatriptan, was also studied in combination with a member of a new class of NSAID, known as COX-2 selective inhibitors, characterized by better tolerability in regard to gastrointestinal side effects. In this study we suggested that a fast acting triptan such as Rizatriptan 10 mg combined with a long plasma half-life COX-2 inhibitor such as Rofecoxib 25 mg reduced recurrence, provided better sustained pain-free rates and demonstrated a trend for better efficacy rates with regard to headache and nausea relief when compared to the single use of Rizatriptan [42]. Recently we have demonstrated that 10 mg Rizatriptan plus 50 mg rofecoxib was more efficient than rizatriptan alone and the combination of rizatriptan plus 200 mg tolfenamic acid with regard to pain-free rates at 2 hours (p = 0.008 and p = 0.007, respectively) and photophobia at 2- and 4-hour timepoints (p = 0.010 and p = 0.023, Rizatriptan + Rofecoxib vs. Rizatriptan; p = 0.003 and p = 0.015, Rizatriptan + Rofecoxib vs. Rizatriptan + Tolfenamic acid). Recurrence was also significantly reduced with both combinations in comparison to rizatriptan alone (50% vs. 15.4%, Rizatriptan vs. rizatriptan + Rofecoxib; 50% vs. 7.7%, Rizatriptan vs. Rizatriptan + Tolfenamic acid). In this study (submitted for publication), 33 patients treated 184 moderate or severe attacks in a randomized counterbalanced order with rizatriptan alone, rizatriptan plus rofecoxib and rizatriptan plus tolfenamic acid. Side effects didn’t differ significantly between the attacks treated with the three options.

**Summary**

Although these evidences clearly suggest advantages with the combination of drugs acting on different mechanisms involved in migraine, there is still a lack of controlled studies to support it. Despite that, drug combinations in migraine treatment are common among specialists. Fortunately, significant recent scientific progress has led to the ability to develop rational polytherapeutic regimes in migraine [14]. We propose that the subset of patients not having achieved pain-free status in up to 2 hours or not presenting sustained pain-free for 24 hours in at least 5 previous migraine attacks with their current acute treatment options undergo combination therapy with simple analgesics or NSAID plus a triptan or a gastro kinetic drug such as 20 mg metoclopramide or 30 mg domperidone or
200 mg trimebutine. The simultaneous use of these three classes of substances must be considered for those still remaining unresponsive to the proposed treatment objectives. In addition, changing the strategy of utilization for the chosen drugs may also improve efficacy and outcome. For those patients rapid developing severe headache, a combination of 6 mg injectable sumatriptan plus 100 mg rectal indometacin seems to be very effective. If nausea is a critical issue for that specific patient the use rectal metoclopramide or the administration of oral domperidone at the first sign of the attack may be useful as well. Patients have to be clearly informed with regard to the drug usage frequency limitations (up to two times a week, not negotiable) since it is not desirable that the potential gained with the drug combination translates into a higher potential for drug overuse. As we break the current paradigm of treating all patients with monotherapy and the clinical experience expands in the future, the perspectives of identifying rapid, consistent and complete polytherapy for migraineurs will develop and certainly solidify and allow maximum efficacy with minimum side effects.

Competing Interests
None declared.

References
1. Stewart WF, Schechter A, Lipton RB: Migraine heterogeneity, disability, pain intensity and attack frequency and duration. Neurology 1994, 44(suppl 4):S24-S39.
2. Rasmussen BK: Epidemiology of headache. Cephalalgia 1995, 15:45-68.
3. Headache Classification Committee of the International Headache Society: Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988, 8(suppl 7):1-96.
4. Stewart WF, Lipton RB, Simon D: Work-related disability: results from the American migraine study. Cephalalgia 1996, 16:231-238.
5. Lipton RB, Stewart WF: Prevalence and impact of migraine. Neurology Clin 1997, 15:1-13.
6. Ferrari MD, Haan J: Drug treatment of migraine attacks. In: Headache. Blue Books of Practical Neurology. Edited by: Goadsby P, Silberstein SD. New York:Butterworth-Heinemann; 1997:117-130.
7. Lipton RB, Diamond S, Reed M, Diamond ML, Stewart WF: Migraine diagnosis and treatment: results from the American Migraine Study II. Headache 2001, 41:638-645.
8. Dodick DW: Acute and prophylactic management of migraine. Clin Cornerstone 2001, 4:36-52.
9. Tfelt-Hansen P, Lipton RB: Prioritizing treatment. In: The Headaches Edited by: Olesen J, Tfelt-Hansen P, Welch KMA. New York: Raven Press; 1993:359-362.
10. Goadsby P, Lipton RB, Ferrari MD: Migraine – Current understanding and treatment. N Engl J Med 2002, 346:257-270.
11. Lipton RB, Stewart WF, Cady R, Hall C, Q’Quinn S, Khun T, Gutterman D: 2000 Wolff Award. Sumatriptan for the range of headaches in migraine sufferers: results of the Spectrum Study. Headache 2000, 40:783-791.
12. Lipton RB, Hamelsky SW, Dayno JM: What do patients with migraine want from acute migraine treatment? Headache 2002, 42(suppl 1):3-9.
13. Saxena P, Tfelt-Hansen P, Triptans, 5-HT1B/1D Receptor Agonists in the acute treatment of Migraine. In: The Headaches Second edition. Edited by: Olesen J. Tfelt-Hansen P, Welch KMA. Philadelphia:Lippincott Williams & Wilkins; 2000:411-438.
14. Peroucha S: Beyond Monotherapy: Rational polytherapy in migraine. Headache 1998, 38:18-22.
15. Bates D, Ashford E, Dawson R, Ensink FB, Gilhus NE, Olesen J, Pilgrim AJ, Shevlin P: Subcutaneous sumatriptan during the migraine brain state. Neurology 1994, 43:1587-1593.
16. Visser VHW, de Vriend RH, Jaspers NHWM, Ferrari MD: Sumatriptan – nonresponders: a survey in 366 migraine patients. Headache 1996, 36:471-475.
17. Dahlöf CG: How does sumatriptan perform in clinical practice? Cephalalgia 1995, 15(suppl 15):21-28.
18. Visser VHW, de Vriend RH, Jaspers NHWM, Ferrari MD: Sumatriptan in clinical practice: a 2-year review of 453 migraine patients. Neurology 1996, 47:46-51.
19. International Headache Society Clinical Trials Subcommittee: Guidelines for controlled trials of drugs in migraine: second edition. International Headache Society. Members Handbook 2002:113-198.
20. Saxena P, Tfelt-Hansen P: Triptans, 5-HT1B/1D Receptor Agonists in the acute treatment of Migraine. In: The Headaches Second edition. Edited by: Olesen J, Tfelt-Hansen P, Welch KMA. Philadelphia:Lippincott Williams & Wilkins; 2000:411-438.
21. Dahlöf C: Placebo-controlled clinical trials with ergotamine in the acute treatment of migraine. Cephalalgia 1993, 13:166-171.
22. Wyss PA, Rosenthaler J, Nuesch E, Aellig WH: Pharmacokinetic investigation of oral and intravenous dihydroergotamine in healthy subjects. Eur J Clin Pharmacol 1991, 41:597-602.
23. Tfelt-Hansen P, Saxena P: Ergot alkaloids in the acute treatment of migraine. In: The Headaches Second edition. Edited by: Olesen J, Tfelt-Hansen P, Welch KMA. Philadelphia:Lippincott Williams & Wilkins; 2000:399-409.
24. Tfelt-Hansen P, McEvon J: Nonsteroidal Anti-inflammatory Drugs in the Acute Treatment of Migraine. In: The Headaches Second edition. Edited by: Olesen J, Tfelt-Hansen P, Welch KMA. Philadelphia:Lippincott Williams & Wilkins; 2000:391-397.
25. Ferrari MD, James MH, Bates D, Pilgrim AJ, Ashford E, Anderson BA, Nappi G: Oral sumatriptan: possible benefit of a second dose, and incidence and treatment of headache recurrences. Cephalalgia 1994, 14:330-8.
26. Krymchantowski AV, Barbosa JS: RizatRIPTAN combined with rofecoxib vs. rizatRIPTAN for the acute treatment of migraine: an open label pilot study. Cephalalgia 2002, 22:309-312.
27. Burstein R: Deconstructing migraine headache into peripheral and central sensitization. Headache. Blue Books of Practical Neurology; 1993:117-130.
28. Ferrari MD: Systemic biochemistry. In: The Headaches Edited by: Olesen J, Tfelt-Hansen P, Welch KMA. New York:Raven Press; 1993:179-183.
29. Ebersberger A, Averbeck B, Messlinger K, Reeh PW: Release of substance P, calcitonin gene-related peptide and prostaglandin E2 from rat dura mater encephali following electrical and chemical stimulation in vitro. Neuroscience 1999, 89:901-907.
30. Moskowitz MA, Macfarlane R: Neurovascular and molecular mechanisms in migraine headaches. Cerebrovasc Brain Metab Rev 1993, 5:159-177.
31. Blau JN, Dexter SL: The site of pain origin during migraine attacks. Cephalalgia 1981, 1:143-147.
32. Burstein R, Yamamura H, Malick A, Strassman AM: Chemical stimulation of the intracranial dura induces enhanced responses to facial stimulation in brain stem trigeminal neurons. J Neurophysiol 1998, 79:964-982.
33. Bini O, Azulay GP, Masson G, Aubrespy G, Serradrice G: Apomorphine-induced yawning in migraine patients: enhanced responsiveness. Clin Neuropharmacol 1991, 14:91-95.
34. Beu A, Guell A, Víctor G, Ben A, Jaume PH, Guix G: Effects of a dopaminergic agonist (Piribedil) on CBF in migraine patients. J Cereb Blood Flow Metabol 1981, 1(suppl 1):S549-S550.
35. Fanciullacci M, Michelacci S, Curradi C, Sicuerti F: Hyperresponsiveness of migraine patients to the hypothensive action of bromocriptine. Headache 1980, 20:99-102.
36. Del Zoppo M, Lai M, Loi V, Pisano MR: Dopamine hypersensitivity in migraine: role in apomorphine syncope. Headache 1995, 35:222-224.
37. Lance JW: Headache. Ann Neurol 1981, 10:1-10.
38. Wilkinson M: Treatment of the acute migraine attack – current status. Cephalalgia 1983, 3:61-67.
39. Callahan M, Raskin N: A controlled study of dihydroergotamine in the treatment of acute migraine headache. Headache 1986, 26:168-171.

40. Krymchantowski AV, Adriano M, Fernandes D: Tolfenamic acid decreases migraine recurrence when used with sumatriptan. Cephalalgia 1999, 19:186-7.
41. Krymchantowski AV: Naproxen sodium decreases migraine recurrence when administered with sumatriptan. Arq Neuropsiquiatr 2000, 58(2-B):428-430.
42. Krymchantowski AV, Barbosa JS: Rizatriptan combined with rofecoxib vs. rizatriptan for the acute treatment of migraine: an open pilot study. Cephalalgia 2002, 22:309-312.

Pre-publication history
The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-2377/4/4/prepub